Historically, decisions to initiate ART have been based on AIDS‐related clinical events, CD4 T‐cell count and comorbidities while trying to limit the risk of drug resistance and reduce ART‐related lipodystrophy and other toxicities 14, 15, 16, 17. The gene discussed is CD4; the disease is lipodystrophy.